Treatment of hypertension in obese patients: focus on telmisartan

I E Deneka,V V Fomin,A V Rodionov

doi:10.15829/1728-8800-2018-6-69-76

Abstract

The article discusses the role of telmisartan in the treatment of arterial hypertension in patients with metabolic syndrome. Telmisartan is second-generation type 1 angiotensin II receptor blocker, which has unique pleiotropic effects due to partial affinity for receptors that activate the proliferation of subtype y peroxisomes (PPARy) located in adipose tissue. The interrelation of metaflamation, a specific chronic inflammatory process with pathogenetic mechanisms of development of cardiovascular diseases, including arterial hypertension, is also described in study. The role of the adiponectin peptide is considered, which synthesis is stimulated by partial PPARy receptor agonists (as mentioned above — telmisartan). It has a positive effect on fat and carbohydrate metabolism, as well as cardioprotective properties. The conclusion contains the results of numerous randomized studies and meta-analyzes confirming the high efficacy of telmisartan in the treatment of arterial hypertension in patients with morbid obesity.

Highlights

The article discusses the role of telmisartan in the treatment of arterial hypertension in patients with metabolic syndrome
Telmisartan is second-generation type 1 angiotensin II receptor blocker, which has unique pleiotropic effects due to partial affinity for receptors that activate the proliferation of subtype γ peroxisomes (PPARγ) located in adipose tissue
The role of the adiponectin peptide is considered, which synthesis is stimulated by partial PPARγ receptor agonists

Summary

Introduction

The article discusses the role of telmisartan in the treatment of arterial hypertension in patients with metabolic syndrome. АГ — артериальная гипертензия, АД — артериальное давление, БРА — блокаторы рецепторов к ангиотензину, ИБС — ишемическая болезнь сердца, ИЛ-6 — интерлейкин-6, ЛВП — липопротеиды высокой плотности, ЛНП — липопротеиды низкой плотности, МС — метаболический синдром, ПРЖК — периренальная жировая клетчатка, СД — сахарный диабет, ССЗ — сердечно-сосудистые заболевания, ФНО-α — фактор некроза опухолей-α, ЧСС — частота сердечных сокращений, NO — оксид азота, PPARγ — рецепторы, активирующие пролиферацию пероксисом подтипа γ, PGC1α,1β — коактиватор рецептора PPAR 1-альфа, 1-бета.

Results

Conclusion